Enovis Corporation (NYSE:ENOV) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Enovis Corporation (NYSE:ENOV) has been assigned an average rating of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $41.2857.

Several analysts have issued reports on the company. BMO Capital Markets restated an “outperform” rating and set a $30.00 price objective on shares of Enovis in a research note on Friday, August 7th. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Wells Fargo & Company dropped their price target on Enovis from $40.00 to $39.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. UBS Group restated a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Finally, Wall Street Zen downgraded shares of Enovis from a “buy” rating to a “hold” rating in a report on Saturday, August 8th.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert purchased 1,200 shares of Enovis stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This represents a 2.37% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have acquired 4,200 shares of company stock worth $92,084 over the last 90 days. 2.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enovis

A number of large investors have recently bought and sold shares of ENOV. Arax Advisory Partners acquired a new position in Enovis in the fourth quarter valued at approximately $29,000. EverSource Wealth Advisors LLC raised its position in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Allworth Financial LP bought a new stake in shares of Enovis in the 2nd quarter worth approximately $36,000. Danske Bank A S bought a new stake in shares of Enovis in the 3rd quarter worth approximately $64,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Enovis during the 2nd quarter valued at approximately $48,000. Institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

Shares of ENOV stock opened at $24.79 on Tuesday. The firm has a fifty day moving average of $24.91 and a two-hundred day moving average of $24.05. The firm has a market cap of $1.43 billion, a P/E ratio of -1.29 and a beta of 1.34. Enovis has a 1-year low of $19.14 and a 1-year high of $34.28. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same quarter in the prior year, the business posted $0.79 EPS. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts anticipate that Enovis will post 3.12 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.